Drug interactions
Indacaterol-glycopyrronium + Inotuzumab
Severity: Moderate
Indacaterol-glycopyrronium and Inotuzumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Inotuzumab ozogamicin is associated with QT prolongation, and beta-agonists such as indacaterol may add to this effect. The combination raises the risk of torsades de pointes in susceptible patients.
What this interaction means in plain words
Indacaterol-glycopyrronium and Inotuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive QT interval prolongation, with beta-agonist-induced hypokalemia as a possible contributor.
What to do
Obtain ECG and electrolytes before starting and periodically during treatment, correcting potassium and magnesium. Switch the bronchodilator if QTc prolongation becomes significant.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Inotuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Inotuzumab?
MediHelp rates the interaction as moderate. Indacaterol-glycopyrronium and Inotuzumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Inotuzumab ozogamicin is associated with QT prolongation, and beta-agonists such as indacaterol may add to this effect. The combination raises the risk of torsades de pointes in susceptible patients.
How serious is the interaction between Indacaterol-glycopyrronium and Inotuzumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain ECG and electrolytes before starting and periodically during treatment, correcting potassium and magnesium. Switch the bronchodilator if QTc prolongation becomes significant.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
